228 related articles for article (PubMed ID: 30719976)
1. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data.
Cassese S; Katagiri Y; Byrne RA; Brugaletta S; Alfonso F; Räber L; Maeng M; Iñiguez A; Kretov E; Onuma Y; Joner M; Sabaté M; Laugwitz KL; Windecker S; Kastrati A; Serruys PW
EuroIntervention; 2020 Mar; 15(16):1451-1457. PubMed ID: 30719976
[TBL] [Abstract][Full Text] [Related]
2. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
3. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study.
Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M;
EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896
[TBL] [Abstract][Full Text] [Related]
4. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
5. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
6. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
7. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
[TBL] [Abstract][Full Text] [Related]
10. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
[TBL] [Abstract][Full Text] [Related]
11. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
[TBL] [Abstract][Full Text] [Related]
13. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
[TBL] [Abstract][Full Text] [Related]
14. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.
Hommels TM; Hermanides RS; Berta B; Fabris E; De Luca G; Ploumen EH; von Birgelen C; Kedhi E
Cardiovasc Diabetol; 2020 Oct; 19(1):165. PubMed ID: 33008407
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
18. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
